DNTH
Dianthus Therapeutics Inc.
88.20$
-0.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -6.8% | +113.2% | -3.5% | -4.0% | +5.6% | -6.8% | -6.5% | +77.1% | -8.1% | +134.9% | -2.7% | |
| – | -7.3% | +114.7% | -4.0% | -21.4% | -2.3% | -3.5% | -2.7% | +57.0% | -1.1% | +173.5% | -19.9% | |
| – | -15.9% | +149.2% | -4.7% | -89.3% | -32.3% | -55.6% | +30.9% | +322.9% | -8.7% | +1,128.6% | -82.4% | |
| – | -8.5% | +117.0% | -4.3% | -22.1% | -2.1% | -4.4% | -2.2% | +56.4% | +0.4% | +174.9% | -20.2% | |
| – | -36.4% | +83.3% | +91.2% | -22.8% | -37.6% | +23.9% | -96.1% | +12,720.5% | -98.0% | +1,105.9% | -91.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -25.2% | -7.2% | +9.9% | +52.2% | +31.7% | -7.2% | +15.1% | +34.8% | +21.1% | +21.5% | -9.5% | |
| – | -26.4% | -7.0% | +11.9% | +56.6% | +17.5% | -8.1% | +18.5% | +18.7% | +28.8% | +24.6% | -10.2% | |
| – | +1.0% | -4.1% | -5.8% | -17.5% | +2.9% | -29.4% | -6.6% | +2.8% | +69.1% | +8.7% | -6.3% | |
| – | +90.7% | +0.1% | +41.5% | +104.9% | -39.5% | +80.6% | -34.6% | +24.1% | +45.0% | -45.8% | +21.2% | |
| – | -5.3% | +120.7% | -3.9% | -5.7% | +4.3% | -6.8% | -7.8% | +80.3% | -9.7% | +143.5% | -2.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -88.4% | +466.5% | +33.4% | +0.0% | +2.3% | +2.2% | +0.1% | +5.5% | +0.0% | +27.1% | +16.6% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.